OTC:WXXWY

WuXi Biologics Signed Letter of Intent for Long-Term Vaccine Manufacturing Contract

SHANGHAI, May 21, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has entered into a strategic partnership L...

2019-05-21 07:30 698

WuXi Biologics Commenced Construction of a 48,000 L Integrated Manufacturing Center for Innovative Biologics in Chengdu

CHENGDU, China, May 16, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that the construction of a new 1.3 million sq. ft....

2019-05-16 15:39 856

WuXi Biologics Successfully Completed First FDA Routine GMP Inspection

SHANGHAI, April 17, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that its Drug Substance (DS) and Drug Product (D...

2019-04-17 09:14 670

WuXi Biologics and I-Mab Biopharma Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs

SHANGHAI, April 16, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and I-Mab Biopharma ("I-Mab"), a biotech company focusing exclus...

2019-04-16 20:00 405

WuXi Biologics and NBE-Therapeutics Announce Comprehensive ADC Development and Manufacturing Partnership

SHANGHAI and BASEL, Switzerland, April 9, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and NBE-Therapeutics (NBE), a privately ow...

2019-04-09 08:36 390

WuXi Biologics Wins 2019 CMO Leadership Awards in All Six Core Categories

SHANGHAI and NEW YORK, April 3, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has received the 2019 CMO Leadersh...

2019-04-03 20:06 438

WuXi Biologics Receives "Asia's Best CMO of 2018" Award from IMAPAC

SHANGHAI and SINGAPORE, March 26, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (Stock Code: 2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has received the "As...

2019-03-26 08:24 404

WuXi Biologics Receives EMA GMP Certificates

SHANGHAI and WUXI, China, March 19, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has received EMA GMP certifica...

2019-03-20 08:07 4153

WuXi Biologics Continues to Deliver Record Results

HONG KONG, March 18, 2019 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announces its aud...

2019-03-18 22:25 608

WuXi Biologics Congratulates Amicus on Receiving FDA Breakthrough Therapy Designation for AT-GAA

- The second product successfully receiving Breakthrough Therapy Designation that WuXi Biologics has enabled its partner to develop SHANGHAI, Feb. 28, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (Stock code: 2269.HK), a leading global open-access biologics technology platform company offe...

2019-02-28 09:52 280

ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Novel Immune Check Point Bispecifics for $220 Million

SHANGHAI and SEOUL, Feb. 26, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and ABL Bio Corporation ("ABL Bio") (298380.KS), a Sout...

2019-02-26 08:23 453

EMA Completed Pre-Approval Inspection of cGMP DS and DP Facilities for Trogarzo (TM) at WuXi Biologics

SHANGHAI, Feb. 19, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that the European Medicines Agency (EMA) has comp...

2019-02-19 14:21 250

EMA Completed Pre-Approval Inspection of cGMP DS and DP Facilities for Trogarzo(TM) at WuXi Biologics

SHANGHAI, Feb. 19, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that the European Medicines Agency (EMA)has compl...

2019-02-19 08:21 291

WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership

SHANGHAI and CRANBURY, N.J., Feb. 12, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Amicus Therapeutics ("Amicus") (Nasdaq: F...

2019-02-12 08:04 306

WuXi Biologics and AC Immune to Establish an Exclusive Strategic Partnership

* AC Immune to draw on WuXi Biologics' expertise in manufacturing innovative New Biological Entities against CNS disorders including proprietary WuXiUP continuous manufacturing platform that can significantly reduce cost of biologics * AC Immune to gain access to WuXi Biologics' proprietary...

2018-12-19 20:16 394

WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development

SHANGHAI, Dec. 13, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company that offers end-to-end solutions for biologics discovery, development and manufacturing, today congratulates its partner Tychan for dosing of first individual in ph...

2018-12-13 07:30 377

WuXi Biologics Achieves Breakthrough Titer of 51g/L in Cell Culture Productivity

SHANGHAI, Dec. 12, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has achieved a breakthrough in cell culture productivi...

2018-12-12 08:08 328

Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million

SHANGHAI and OXFORD, the United Kingdom, Dec. 11, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing and Oxford BioTherapeutics Ltd. ("OBT"), a clini...

2018-12-11 15:00 310

Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million

SHANGHAI and OXFORD, the United Kingdom, Dec. 10, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing and Oxford BioTherapeutics Ltd. ("OBT"), a cl...

2018-12-11 09:47 350

WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics

SHANGHAI, Dec. 10, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced today a strategic collaboration with Brii Biosciences (Brii Bio), an...

2018-12-10 10:21 414
1234